Reata Pharmaceuticals Inc expected to post a loss of $2.31 a share - Earnings Preview

Reata Pharmaceuticals

25/02/2022 15:39

* Reata Pharmaceuticals Inc  RETA.OQ   RETA.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
28. 
    * The Plano Texas-based  company is expected to report  a
49.0% decrease in revenue to $1.627 million from $3.19 million a
year ago, according to the mean estimate from 7 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Reata
Pharmaceuticals Inc
is for a loss of $2.31 per share. For the same quarter last
year, the company reported a loss of $1.90 per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $43​, about 40.5% above​ its last closing
price of $25.58. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -2.16       -2.16      -1.97     Beat    9
 Jun. 30 2021  -2.02       -2.06      -2.00     Beat    2.8
 Mar. 31 2021  -2.08       -2.10      -1.86     Beat    11.3​
 Dec. 31 2020  -2.15       -2.16      -1.90     Beat    11.9
 ​​Sep.        -1.99       -1.98      -1.94     Beat    1.9
 30 2020                                                
 Jun. 30 2020  -4.07       -2.84      -1.67     Beat    41.1​
 Mar. 31 2020  -1.91       -1.98      -1.47     Beat    25.6
 Dec. 31 2019  -6.05       -5.15      -1.59     Beat    69.1
 This summary was machine generated February 25 at 15:39 GMT. 
All figures in US dollars  unless otherwise stated